Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palonosetron intravenous - Helsinn Healthcare

Drug Profile

Palonosetron intravenous - Helsinn Healthcare

Alternative Names: 2-QHBIQO; Aloxi Injection; Nuowei; ONICIT; Onicit; Palonosetron hydrochloride; Paloxi; RS-25259; RS-25259-197; RS-42358-197

Latest Information Update: 22 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer CJ HealthCare; Helsinn; Taiho Pharmaceutical
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting

Most Recent Events

  • 15 Aug 2018 Mundipharma signs licensing and distribution agreement for palonosetron with Helsinn in Vietnam
  • 28 Jun 2018 Helsinn obtained distributorship for intravenous palonosetron in USA
  • 26 Jun 2018 The US Supreme Court grants certiorari to review a Federal Circuit Panel decision for petition by Helsinn regarding patent claims covering intravenous palonosetron
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top